Neurocrine Biosciences Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $1.37B | $340.8M |
| FY2022 | — | $1.71B | $262.9M |
| FY2023 | — | $2.23B | $251.1M |
| FY2024 | — | $2.59B | $233.0M |
| FY2025 | — | $3.25B | $713.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $1.37B | $340.8M |
| FY2022 | — | $1.71B | $262.9M |
| FY2023 | — | $2.23B | $251.1M |
| FY2024 | — | $2.59B | $233.0M |
| FY2025 | — | $3.25B | $713.0M |